Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18).
Video Library —October 20, 2021
Categories:
Interview with the InnovatorsLast modified: August 10, 2023